{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:34:54Z","timestamp":1793072094064,"version":"4.5.0"},"reference-count":8,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes"],"published-print":{"date-parts":[[2026,10]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n Urinary liver\u2010type fatty acid\u2010binding protein (L\u2010FABP) reflects proximal tubular stress and has been proposed as a biomarker of diabetic kidney disease. We examined whether urinary L\u2010FABP provides information on longitudinal kidney function beyond urinary albumin\u2010to\u2010creatinine ratio (UACR).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This retrospective cohort study included patients with type 2 diabetes who had UACR and urinary L\u2010FABP measured simultaneously at the initial visit and underwent outpatient follow\u2010up. The analysis included patients with at least three eGFR measurements over at least 2\u2009years. eGFR trajectories were evaluated using linear mixed\u2010effects models with random intercepts and slopes. UACR and L\u2010FABP were analyzed as log(1\u2009+\u2009\n x<\/jats:italic>\n )\u2010transformed continuous variables.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The analysis included 1,031 patients (age 58.1\u2009years; 65.1% men), with a median follow\u2010up of 4.76\u2009years and a median of 10 eGFR measurements. Urinary L\u2010FABP correlated with UACR (Spearman\n \u03c1<\/jats:italic>\n \u2009=\u20090.526;\n p<\/jats:italic>\n \u2009<\u20090.001). Both biomarkers were independently associated with lower baseline eGFR. In a model without UACR, higher L\u2010FABP was associated with faster eGFR decline (\u22120.98 mL\/min\/1.73\u2009m\u00b2\/year per unit increase in log[1\u2009+\u2009L\u2010FABP];\n p<\/jats:italic>\n \u2009<\u20090.001). After adjustment for continuous UACR, the association was attenuated and no longer significant (\u22120.19; 95% CI, \u22120.49 to 0.11;\n p<\/jats:italic>\n \u2009=\u20090.221), whereas UACR remained independently associated with eGFR decline. Results were unchanged after further adjustment for baseline eGFR and lipid parameters.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Urinary L\u2010FABP was associated with baseline kidney impairment but did not independently predict eGFR trajectory after continuous UACR was taken into account. Urinary L\u2010FABP reflects kidney injury severity, although its incremental prognostic value beyond quantitatively assessed albuminuria was limited in this cohort.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/1753-0407.70285","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:51:33Z","timestamp":1792209093000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Urinary Liver\u2010Type Fatty Acid\u2010Binding Protein, Albuminuria, and\n eGFR<\/scp>\n Trajectories in Type 2 Diabetes"],"prefix":"10.1111","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0353-5807","authenticated-orcid":false,"given":"Hiroaki","family":"Satoh","sequence":"first","affiliation":[{"name":"Department of Diabetes and Endocrinology Juntendo University Urayasu Hospital Urayasu Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4179-0175","authenticated-orcid":false,"given":"Shotaro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology Juntendo University Urayasu Hospital Urayasu Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Haba","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology Juntendo University Urayasu Hospital Urayasu Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sekine","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology Juntendo University Urayasu Hospital Urayasu Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0943-0712","authenticated-orcid":false,"given":"Daisuke","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology Juntendo University Urayasu Hospital Urayasu Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"4","key":"e_1_2_1_11_2_1","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes CKD Work Group","year":"2024","journal-title":"Kidney International"},{"key":"e_1_2_1_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300\u2010025\u201001731\u2010w"},{"key":"e_1_2_1_11_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1392"},{"key":"e_1_2_1_11_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1298"},{"key":"e_1_2_1_11_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1868"},{"key":"e_1_2_1_11_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054863"},{"key":"e_1_2_1_11_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"e_1_2_1_11_9_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019010008"}],"container-title":["Journal of Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1753-0407.70285","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1753-0407.70285","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1753-0407.70285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:12:10Z","timestamp":1793070730000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1753-0407.70285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":8,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/1753-0407.70285"],"URL":"https:\/\/doi.org\/10.1111\/1753-0407.70285","archive":["Portico"],"relation":{},"ISSN":["1753-0393","1753-0407"],"issn-type":[{"value":"1753-0393","type":"print"},{"value":"1753-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2026-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70285"}}